Lymphoma is a type of blood cancer that occurs when T or B lymphocytes grow abnormally. In addition, it also occurs if the cells survive longer than their normal life-cycle. There are mainly two types of lymphocytes that can be developed into lymphomas in the body namely, B-lymphocytes (B-cells) and T-lymphocytes (T-cells). Angioimmunoblastic T-Cell Lymphoma (AILT) is a rare and aggressive T-cell lymphoma that accounts for 1% to 2% of the total non-Hodgkin lymphoma (NHL) cases in the U.S. AILT is also known as Angioimmunoblastic lymphadenopathy with dysproteinemia.
Chemotherapy is one of the most common treatment for AILT, as it destroys the cancer cells by obstructing its division process. Various drugs are in clinical trial phases for the treatment of AILT along with chemotherapy sessions or alone. Below mentioned are the names of few drugs in pipeline for the same: Alemtuzumab (Campath) Bevacizumab (Avastin) Cyclosproine (Neoral, Sandimmune, Gengraf) Lenalidomide (Revlimid) Romidepsin (Istodax) Pralatrexate (Folotyn)
Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/angioimmunoblastic-t-cell-lymphoma-market.html
Rising incidences of lymphoma globally would accentuate the growth of lymphoma treatment drugs Leukemia and Lymphoma Society estimated that, in 2012, around 700,000 people were diagnosed with lymphoma in Canada region alone. The U.S. and European government amplified their funding for R&D activities on the drugs utilized for the treatment of lymphoma which would further propel the growth of this market. Moreover, increasing government initiatives for patient awareness about lymphoma and its treatments also drives the growth of this market. Despite all the above mentioned advantages, side-effects (hair loss, nausea, vomiting and fatigue) of chemotherapy might restrict the growth of this market. In addition, high cost of chemotherapy treatment would hamper the growth of this market. Moreover, regions such as the U.K are not providing favorable reimbursement policy for lymphoma treating drug which would restrain the growth in this region.
Various key players engaged in developing drugs for the treatment of AILT are Takeda Pharmaceutical Company Limited, Newport Pharmaceuticals Ltd., Eisai, Inc., Cellerant Therapeutics, Inc. and others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=33953&source=atm
The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis
The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=33953&source=atm